Schonfeld Strategic Advisors LLC Neurocrine Biosciences Inc Transaction History

Schonfeld Strategic Advisors LLC

$13.8 Billion
Q3 2024

A detailed history of Schonfeld Strategic Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 24,282 shares of NBIX stock, worth $2.99 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

24,282

Previous 30,413 20.16%

Holding current value

$2.99 Million

Previous $4.19 Million 33.23%

% of portfolio

0.02%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $702,489 - $938,962	-6,131 Reduced 20.16%	24,282 $2.8 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $2.26 Million - $2.47 Million	-17,281 Reduced 36.23%	30,413 $4.19 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $10.5 Million - $11.6 Million	-80,675 Reduced 62.85%	47,694 $6.58 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $10.5 Million - $13.2 Million	99,360 Added 342.51%	128,369 $16.9 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $1.21 Million - $1.51 Million	-12,895 Reduced 30.77%	29,009 $3.26 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $4.68 Million - $5.48 Million	-52,258 Reduced 55.5%	41,904 $3.95 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $4.38 Million - $5.73 Million	46,562 Added 97.82%	94,162 $9.53 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $2.33 Million - $2.78 Million	-21,843 Reduced 31.45%	47,600 $5.69 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $3.01 Million - $3.53 Million	32,722 Added 89.11%	69,443 $7.38 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $2.8 Million - $3.7 Million	-36,986 Reduced 50.18%	36,721 $3.58 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $3.44 Million - $4.5 Million	-47,511 Reduced 39.19%	73,707 $6.91 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $9.66 Million - $12.9 Million	121,218 New	121,218 $10.3 Million
Q3 2021 Nov 16, 2021	SELL	$86.18 - $99.03 $1.71 Million - $1.96 Million	-19,800 Closed	0 $0
Q2 2021 Nov 16, 2021	SELL	$89.43 - $102.27 $44,715 - $51,135	-500 Reduced 2.46%	19,800 $1.93 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $1.82 Million - $2.08 Million	20,300 New	20,300 $1.98 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $3.18 Million - $3.96 Million	-36,551 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $3.04 Million - $4.27 Million	31,592 Added 637.06%	36,551 $4,000
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $209,151 - $320,424	2,458 Added 98.28%	4,959 $605,000
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $1.67 Million - $2.52 Million	-22,183 Reduced 89.87%	2,501 $216,000
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $3.42 Million - $4.67 Million	-39,416 Reduced 61.49%	24,684 $2.65 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $2.2 Million - $2.66 Million	26,200 Added 69.13%	64,100 $5.78 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $1.18 Million - $1.5 Million	-16,400 Reduced 30.2%	37,900 $3.2 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $3.43 Million - $4.53 Million	-49,489 Reduced 47.68%	54,300 $4.78 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $3.67 Million - $6.69 Million	53,789 Added 107.58%	103,789 $7.41 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $494,400 - $629,250	-5,000 Reduced 9.09%	50,000 $6.15 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $1.49 Million - $2.1 Million	19,793 Added 56.22%	55,000 $5.4 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $321,579 - $391,718	4,238 Added 13.68%	35,207 $2.92 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $1.45 Million - $1.92 Million	-24,711 Reduced 44.38%	30,969 $2.4 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $2.67 Million - $3.41 Million	55,680	55,680 $3.41 Million

Others Institutions Holding NBIX

# of Institutions

624

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account

Schonfeld Strategic Advisors LLC Neurocrine Biosciences Inc Transaction History